CA19-9 in Potentially Resectable Pancreatic Cancer: Perspective to Adjust Surgical and Perioperative Therapy
Top Cited Papers
- 18 December 2012
- journal article
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 20 (7) , 2188-2196
Abstract
Purpose In pancreatic cancer, genetic markers to aid clinical decision making are still lacking. The present study was designed to determine the prognostic role of perioperative serum tumor marker...Keywords
This publication has 32 references indexed in Scilit:
- Pancreatic Cancer Surgery in the New MillenniumAnnals of Surgery, 2011
- Estimating prognosis and palliation based on tumour marker CA 19-9 and quality of life indicators in patients with advanced pancreatic cancer receiving chemotherapyBritish Journal of Cancer, 2010
- Predictive and Prognostic Value of CA 19-9 in Resected Pancreatic AdenocarcinomaJournal of Gastrointestinal Surgery, 2009
- Resectable Pancreatic Cancer: Who Really Benefits From Resection?Annals of Surgical Oncology, 2009
- Preoperative CA 19-9 and the Yield of Staging Laparoscopy in Patients with Radiographically Resectable Pancreatic AdenocarcinomaAnnals of Surgical Oncology, 2008
- CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trialThe Lancet Oncology, 2008
- Carbohydrate antigen 19·9 accurately selects patients for laparoscopic assessment to determine resectability of pancreatic malignancyBritish Journal of Surgery, 2007
- Perioperative CA19-9 Levels Can Predict Stage and Survival in Patients With Resectable Pancreatic AdenocarcinomaJournal of Clinical Oncology, 2006
- CA 19-9 Levels Predict Results of Staging Laparoscopy in Pancreatic CancerJournal of Gastrointestinal Surgery, 2005
- CA19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trialsBritish Journal of Cancer, 2005